Post by Noah Pines

One investment is interesting. Two starts to look like a strategy. Just a few weeks after investing in #Abridge to support AI-enabled clinical trial recruitment, Eli Lilly has now taken an equity stake in #Oura, the wearable ring company. On the surface, the two investments seem unrelated. But taken together, they suggest Lilly is thinking well beyond the pill itself. Oura brings continuous streams of patient-generated personal health data, while Abridge captures clinical conversations and workflows. Together, they represent two very different vistas on the patient journey. One follows patients between visits; the other helps understand what happens during the visit. I've written quite a bit over the past year about AI, wearables, and the growing role of longitudinal health data. Increasingly, it feels like the future of healthcare won't simply be defined by better therapeutics. It will also be shaped by better context: continuous, real-world information that helps patients, HCPs, and researchers understand what happens before, during, and after treatment. It's an interesting direction, and one that we'll be watching closely. Michael Hersman Indrajit Mitra Arvind Balasundaram Derek Fetzer John Capano, PhD Catie Barbieri Tim Brewer William Leopold Brittney Rakestraw Sharon Tessler Nipa Clayton Brian Hull Tom Nolte Himavanth Chandra Thani Jambulingam, Ph.D. Jesse Pines Ibrahim Mian, MD Audrey Wu #DigitalHealth #Wearables #AIinHealthcare #GLP1 #ClinicalTrials #PatientEngagement #HealthTech #Pharma #Biotech